GLP-1 weight-loss medications linked to reduced alcohol consumption

Emerging research suggests that GLP-1 medications, such as Ozempic, Wegovy, and Mounjaro, may reduce alcohol consumption by affecting the brain's reward response. These drugs, which contain semaglutide or tirzepatide, are primarily used for weight loss by mimicking hormones that suppress appetite.

Studies have indicated potential links to reduced cravings. Dr. Christian Hendershot of the University of South Carolina published a 2025 study showing participants with alcohol use disorder experienced fewer cravings while taking Ozempic. Additionally, research from the University of Colorado Anschutz suggested that oral GLP-1 medications led to fewer days of heavy drinking among individuals with mild to moderate alcohol use disorder.

Users have reported various experiences, including diminished cravings, increased nausea or fullness when drinking, and getting intoxicated more quickly. However, some users reported no noticeable change in their relationship with alcohol.